The Center for Multiple Sclerosis and Neuroimmunology at Hadassah

Directions Website

The Center for Multiple Sclerosis and Neuroimmunology at Hadassah The Hadassah Centre for MS and Neuroimmunology provides a multi-disciplinary approach to the problems related to MS and other neuroinflammatory diseases Prof.

The Center for Multiple Sclerosis (MS) at Hadassah is a multidisciplinary center that coordinates the treatment and follow-up of multiple sclerosis patients in the Jerusalem area and its surroundings, and is a reference center for patients all over the country and abroad. In the Center there are neurologists who are an experts in multiple sclerosis, a nurse and a social worker, a psychologist, and advisors on visual problems and urological problems. In addition the Center is located in close contact with the Center for Rehabilitation at Har HaTsofim. The follow-up on the patient is done in the clinic which is open daily. The clinic may be reached by telephone at 02-6776939. Patients are examined by doctors of the Center (Prof. Karussis, Dr. Vaknin-Dembinsky, Dr. Petrou) and by physicians from the Department of Neurology (Prof. Abramsky, Professor Ben-Hur, Dr. Ponger, Dr. Yghmour). Patients can receive an evaluation of their situation from specialists in urology (urinary and sexual problems), rehabilitation (motor problems), and neuropthalmology (vision problems). In the Center, the patients are evaluated using novel immunological tests (detection of antibodies against interferons, detection of antibodies directed against proteins of the white matter in the brain and spinal cord). These tests can help to diagnose the disease more accurately and to classify it according to immunologic characteristics to ensure an effective treatment adjusted for each patient. The patient can also receive advice regarding his/her unique social needs from a nurse (Michal Mor) and social worker, both with many years of experience in treating patients with multiple sclerosis. What distinguishes our Center is the combination of excellent clinical care together with immunological research performed in the Neuroimmunological Laboratory and the Department of Neurology, which allow the development and direct implementation of innovative therapies for the disease. For example, the novel immunomodulatory drugs Linomide and Laquinimod, treatment of vaccination with T-cell lymphocytes and transplantation of stem cells (bone marrow transplants and transplants of STROMA cells as a treatment to encourage neurogenesis (new growth of neurons and myelin forming cells) and protect brain tissue from the progression of brain damage). Therapeutic cell transplants were first developed in our lab and in the Center for MS and in most cases are given only in the framework of clinical trials solely at the Center for MS at Hadassah Medical Center, Jerusalem. Dimitrios Karussis, expert in neuroimmunology and Israeli representative in the great European forums related to multiple sclerosis, Director of the new Center for MS at Hadassah under the auspices of the Director of the Department Prof. Tamir Ben-Hur,. Dimitrios Karussis has in recent years initiated various clinical studies with novel drugs such as Linomide, with T cell vaccination and with stem cell transplantation in MS. This therapeutic project has recently received a boost through collaboration with other centers in the world.

ื”ืžืจื›ื– ืœื˜ืจืฉืช ื ืคื•ืฆื” ื‘ื”ื“ืกื”
ื”ืžืจื›ื– ืœื˜ืจืฉืช ื ืคื•ืฆื” ื‘ื”ื“ืกื”, ื”ื•ื ืžืจื›ื– ืจื‘ ืชื—ื•ืžื™ ื”ืžืจื›ื– ืืช ื”ื˜ื™ืคื•ืœ ื•ื”ืžืขืงื‘ ื‘ื—ื•ืœื™ ื˜ืจืฉืช ื ืคื•ืฆื” ื‘ืื™ื–ื•ืจ ื™ืจื•ืฉืœื™ื ื•ื”ืกื‘ื™ื‘ื” ื•ืžื”ื•ื•ื” REFERENCE CENTER ืœื—ื•ืœื™ื ืžืจื—ื‘ื™ ื”ืืจืฅ ื•ืžื—ื•"ืœ.

ืจื•ืคืื™ ื”ืžืจื›ื–:
ื”ื—ื•ืœื™ื ื ื‘ื“ืงื™ื ื”ืŸ ืขืœ ื™ื“ื™ ืจื•ืคืื™ื ืฉืœ ื”ืžืจื›ื– (ืคืจื•ืค. ืงืจื•ืกื™ืก, ื“ืดืจ ื•ืงื ื™ืŸ, ื“ืดืจ ืคื˜ืจื•, ื“ืดืจ ื•ื•ืจื‘ืจ)
ื•ื”ืŸ ืขืœ ื™ื“ื™ ืจื•ืคืื™ื ืžื”ืžื—ืœืงื” ื”ื ื•ื™ืจื•ืœื•ื’ื™ืช (ืคืจื•ืค. ื‘ืŸ-ื—ื•ืจ, ืคืจื•ืค. ืื‘ืจืžืกืงื™, ื“ืดืจ ื—ื•ืจื™ ื•ืื—ืจื™ื). ื•ืžืงื‘ืœื™ื ื‘ื ื•ืกืฃ ื”ืขืจื›ื” ืข"ื™ ืจื•ืคืื™ื ืžื•ืžื—ื™ื ื‘ืื•ืจื•ืœื•ื’ื™ื” (ื“ืจื›ื™ ื”ืฉืชืŸ ื•ื‘ืขื™ื•ืช ืžื™ืŸ), ืฉื™ืงื•ื (ื‘ืขื™ื•ืช ืžื•ื˜ื•ืจื™ื•ืช), ื›ืื‘ื™ื ื•ืกืคืกื˜ื™ื•ืช, ื ื•ื™ืจื•ืื•ืคืชืœืžื•ืœื•ื’ื™ื” (ื‘ืขื™ื•ืช ืจืื™ื™ื”) ื•ืข"ื™ ืคืกื™ื›ื•ืœื•ื’ ื”ืžืจื›ื– (ืœื‘ืขื™ื•ืช ืคืกื™ื›ื•ืœื•ื’ื™ื•ืช ื•ืงื•ื’ื ื˜ื™ื‘ื™ื•ืช).

ื”ืขืจื›ืช ื”ื—ื•ืœื” ื‘ืžืจื›ื– ืœื˜ืจืฉืช ื ืคื•ืฆื”
ื‘ืžืจื›ื– ืœื˜ื™ืคื•ืœ ื•ืื‘ื—ื•ืŸ ื˜ืจืฉืช ื ืคื•ืฆื” ื”ื—ื•ืœื™ื ืขื•ื‘ืจื™ื ื”ืขืจื›ื” ื”ื›ื•ืœืœืช ื‘ื“ื™ืงื•ืช ืื™ืžื•ื ื•ืœื•ื’ื™ื•ืช ื—ื“ื™ืฉื•ืช ื›ื’ื•ืŸ ื–ื™ื”ื•ื™ ื ื•ื’ื“ื ื™ื ื›ื ื’ื“ ืื™ื ื˜ืจืคืจื•ื ื™ื, ื–ื™ื”ื•ื™ ื ื•ื’ื“ื ื™ื ื”ืžื›ื•ื•ื ื™ื ื›ื ื’ื“ ื—ืœื‘ื•ื ื™ื ืฉืœ ื”ื—ื•ืžืจ ื”ืœื‘ืŸ ื‘ืžื•ื— ื•ื—ื•ื˜ ื”ืฉื“ืจื” ื•ืขื•ื“. ื‘ื“ื™ืงื•ืช ืืœื• ื™ื›ื•ืœื•ืช ืœืขื–ื•ืจ ืœืื‘ื—ื•ืŸ ืžื“ื•ื™ืง ื™ื•ืชืจ ืฉืœ ื”ืžื—ืœื” ื•ืœืกื•ื•ื’ ืฉืœ ื”ืžื—ืœื” ืืฆืœ ื›ืœ ื—ื•ืœื” ื•ื—ื•ืœื” ืขืœ ืคื™ ืžืืคื™ื™ื ื™ื ืื™ืžื•ื ื•ืœื•ื’ื™ื, ืขืœ ืžื ืช ืœื”ืชืื™ื ื˜ื™ืคื•ืœ ื™ืขื™ืœ, ื‘ืื•ืคืŸ ืื™ืฉื™ (individualized).
ื›ืžื• ื›ืŸ, ื ื™ืชืŸ ืœืงื‘ืœ ื™ืขื•ืฅ ืœืฆืจื›ื™ื ื”ืกื•ืฆื™ืืœื™ื™ื ื”ื™ื—ื•ื“ื™ื™ื ืฉืœ ื”ื—ื•ืœื™ื ื‘ืขื–ืจืชืŸ ืฉืœ ืื—ื•ืช (ื’ื‘' ืžื™ื›ืœ ืžื•ืจ) ื•ืขื•ื‘ื“ืช ืกื•ืฆื™ืืœื™ืช (ื’ื‘' ืฉื•ืฉื™ ืงืจืŸ), ืฉืชื™ื”ืŸ ืขื ื ืกื™ื•ืŸ ืจื‘ ืฉื ื™ื ื‘ื˜ื™ืคื•ืœ ื‘ื—ื•ืœื™ ื˜ืจืฉืช ื ืคื•ืฆื”

ื”ืžื™ื™ื—ื“ ืืช ื”ืžืจื›ื– ื”ื—ื“ืฉ ื”ื•ื ื”ืฉื™ืœื•ื‘ ืฉืœ ื”ื˜ื™ืคื•ืœ ื”ืงืœื™ื ื™ ื™ื—ื“ ืขื ื”ืžื—ืงืจ ื”ืื™ืžื•ื ื•ืœื•ื’ื™ ืฉืžืชื‘ืฆืข ื‘ืžืขื‘ื“ื” ื”ื ื•ื™ืจื•ืื™ืžื•ื ื•ืœื•ื’ื™ืช ื•ื”ืžื—ืœืงื” ื”ื ื•ื™ืจื•ืœื•ื’ื™ืช, ืฉืžืืคืฉืจื™ื ืคื™ืชื•ื— ื•ื™ืฉื•ื ื™ืฉื™ืจ ืฉืœ ื˜ื™ืคื•ืœื™ื ื—ื“ืฉื ื™ื™ื ืœืžื—ืœื” , ืœื“ื•ื’ืžื, ืฉื™ืžื•ืฉ ื‘ืชืจื•ืคื•ืช ืื™ืžื•ื ื•ืžื•ื“ื•ืœื˜ื•ืจื™ื•ืช ื—ื“ื™ืฉื•ืช ( LINOMIDE ื•- LAQUINIMOD ), ื˜ื™ืคื•ืœ ืขื ื—ื™ืกื•ืŸ ืขืœ ื™ื“ื™ ืชืื™ื™ื ืœื™ืžืคื•ืฆื™ื˜ืืจื™ื ืžืกื•ื’ -T , ื•ื”ืฉืชืœื•ืช ืชืื™ ื’ื–ืข (ื”ืฉืชืœื•ืช ืžื— ืขืฆืžื•ืช ื•ื”ืฉืชืœื•ืช ืชืื™ MSC ื›ื˜ื™ืคื•ืœ ืœืขื™ื“ื•ื“ ืฆืžื™ื—ื” ื—ื“ืฉื” ืฉืœ ื ื•ื™ืจื•ื ื™ื ื•ืชืื™ื ื™ื•ืฆืจื™ ืžื™ืืœื™ืŸ, ื•ื”ื’ื ื” ืขืœ ืจืงืžืช ื”ืžื•ื—. ื˜ื™ืคื•ืœื™ ื”ืฉืชืœื•ืช ืชืื™ื ืคื•ืชื—ื• ืœืจืืฉื•ื ื” ื‘ืžืขื‘ื“ืชื™ื ื• ื•ื ื™ืชื ื™ื ื‘ืžืกื’ืจืช ื ื™ืกื•ื™ื™ื ืงืœื™ื ื™ื™ื ืืš ื•ืจืง ื‘ืžืจื›ื– ืœื˜ืจืฉืช ื ืคื•ืฆื” ื‘ืžืจื›ื– ืจืคื•ืื™ ื”ื“ืกื”, ื‘ื™ืจื•ืฉืœื™ื.

ืคืจื•ืค. ื“ื™ืžื™ื˜ืจื™ื•ืก ืงืจื•ืกื™ืก, ืžื•ืžื—ื” ืœื ื•ื™ืจื•ืื™ืžื•ื ื•ืœื•ื’ื™ื” (ื•ื™ื•"ืจ ื”ื—ื‘ืจื” ื”ื™ืฉืจืืœื™ืช ืœื ื•ื™ืจื•ืื™ืžื•ื ื•ืœื•ื’ื™ื”) ื•ื ืฆื™ื’ ื™ืฉืจืืœ ื‘ืคื•ืจื•ืžื™ื ื”ืื™ืจื•ืคืื™ื ื”ื’ื“ื•ืœื™ื ื”ืงืฉื•ืจื™ื ืœื˜ืจืฉืช ื ืคื•ืฆื”, ืžื ื”ืœ ืืช ื”ืžืจื›ื– ื”ื—ื“ืฉ ืœื˜ืจืฉืช ื‘ื”ื“ืกื”. ืคืจื•ืค' ืงืจื•ืกื™ืก ื™ื–ื ื‘ืฉื ื™ื ื”ืื—ืจื•ื ื•ืช ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื ืฉื•ื ื™ื ืขื ืชืจื•ืคื•ืช ื—ื“ื™ืฉื•ืช ื›ืžื• ืœื™ื ื•ืžื™ื™ื“, ืขื ื—ื™ืกื•ืŸ ืข"ื™ ืชืื™ T ื•ืขื ื”ืฉืชืœื•ืช ืชืื™ ื’ื–ืข ื‘ื˜ืจืฉืช ื ืคื•ืฆื”. ืคืจื•ื™ื™ืงื˜ ื˜ื™ืคื•ืœื™ ื–ื” ืžืงื‘ืœ ืœืื—ืจื•ื ื” ืชื ื•ืคื” ืชื•ืš ืฉื™ืชื•ืฃ ืคืขื•ืœื” ืขื ืžืจื›ื–ื™ื ืื—ืจื™ื ื‘ืขื•ืœื, ื•ืžื”ื•ื•ื” ืชืงื•ื” ื’ื“ื•ืœื” ืœื›ืœ ื”ืžื—ืœื•ืช ื”ื ื™ื•ื•ื ื™ื•ืช ืฉืœ ืžืขืจื›ืช ื”ืขืฆื‘ื™ื.

16/03/2020

ื ื™ื™ืจ ืขืžื“ื” ืฉืœ ื”ื—ื‘ืจื” ื”ื™ืฉืจืืœื™ืช ืœื ื•ื™ืจื•ืื™ืžื•ื ื•ืœื•ื’ื™ื” ื•ื”ืื’ื•ื“ื” ื”ื™ืฉืจืืœื™ืช ืœื˜ืจืฉืช ื ืคื•ืฆื” ืœื’ื‘ื™ ืžื’ื™ืคืช ื”ืงื•ืจื•ื ื”

ืื ืฉื™ื ืขื ื˜ืจืฉืช ื ืคื•ืฆื” ืžื˜ื•ืคืœื™ื ื‘ืžื’ื•ื•ืŸ ืชืจื•ืคื•ืช, ื—ืœืงืŸ ืžื•ื•ืกืชื•ืช ื•ื—ืœืงืŸ ืžื“ื›ืื•ืช ืืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ. ื‘ืื•ืคืŸ ื˜ื‘ืขื™ ืžืชืขื•ืจืจื•ืช ืฉืืœื•ืช ื”ืงืฉื•ืจื•ืช ืœืืคื™ื“ืžื™ื” ื”ืขื•ืœืžื™ืช ื‘ื ื’ื™ืฃ ื”ืงื•ืจื•ื ื” COVID-19 ื•ืœืกื™ื›ื•ืŸ ืฉืœ ื—ื•ืœื™ ื˜ืจืฉืช ื ืคื•ืฆื” (ืžื˜ื•ืคืœื™ื ืื• ืœื) ืœืœืงื•ืช ื‘ืžื—ืœื”.
ื ื’ื™ืฃ ื”ืงื•ืจื•ื ื” ืžื•ืขื‘ืจ ืžืื“ื ืœืื“ื ื‘ืขื™ืงืจ ื‘ืžื’ืข ื•ื”ืขื‘ืจื” ื˜ื™ืคืชื™ืช (ื˜ื™ืคื•ืช ืจื•ืง, ืฉื™ืขื•ืœ, ื”ืชืขื˜ืฉื•ืช). . ืžืขืจื™ื›ื™ื ืฉืžืจื‘ื™ืช ื”ื ื“ื‘ืงื™ื ื‘ื ื’ื™ืฃ ื ื•ืฉืื™ื ืื•ืชื• ืœืœื ืชืกืžื™ื ื™ื ืื• ืžืคืชื—ื™ื ืชืกืžื™ื ื™ื ืงืœื™ื ื‘ืœื‘ื“, ื•ืจืง ื—ืœืง ืงื˜ืŸ ื™ืคืชื— ืžื—ืœื” ืงืฉื” ื™ื•ืชืจ ืขื ื“ืœืงืช ืจื™ืื•ืช. ื’ื•ืจืžื™ ืกื™ื›ื•ืŸ ืœืžื—ืœื” ืงืฉื” ื™ื•ืชืจ ื›ื•ืœืœื™ื ื’ื™ืœ ืžื‘ื•ื’ืจ ื•ืžื—ืœื•ืช ื›ืจื•ื ื™ื•ืช ื›ืžื• ืžื—ืœื•ืช ืœื‘, ืจื™ืื” ืื• ืกื›ืจืช. ืื™ืŸ ืžื™ื“ืข ืœื’ื‘ื™ ื”ืกื™ื›ื•ืŸ ื‘ืื ืฉื™ื ื”ืžื˜ื•ืคืœื™ื ื‘ืชืจื•ืคื•ืช ื”ืžื“ื›ืื•ืช ืืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ, ืื• ืขื ื”ื’ื‘ืœื” ืชืคืงื•ื“ื™ืช ืงืฉื”, ืื•ืœื ื”ื”ืขืจื›ื” ื”ื™ื ืฉื”ืŸ ืขืœื•ืœื•ืช ืœื”ื’ื‘ื™ืจ ืืช ื”ืกื™ื›ื•ืŸ ืœื”ื“ื‘ืง ื‘ื ื’ื™ืฃ ื•ืœืคืชื— ืžื—ืœื” ืงืฉื” ื™ื•ืชืจ. ื”ืžื—ืœื” ื”ื™ื ื‘ืขืœืช ืฉื™ืขื•ืจ ื”ื“ื‘ืงื” (R0, ื‘ื™ื˜ื•ื™ ืœืžืกืคืจ ื”ื ื“ื‘ืงื™ื ืžื›ืœ ื—ื•ืœื” ื‘ื•ื“ื“ ื‘ื ื’ื™ืฃ ื”ืงื•ืจื•ื ื”) ืฉืœ 2-4 (ืœืฉื ื”ืฉื•ื•ืื” ื”ืฉื™ืขื•ืจ ื‘ืฉืคืขืช ืขื•ื ืชื™ืช ื”ื•ื 1.2 ื•ื‘ื—ืฆื‘ืช โ€“ 15). ืœืคื™ ืžืกืคืจื™ื ืžืกื™ืŸ, ืฉื™ืขื•ืจ ื”ืชืžื•ืชื” ื‘ื—ื•ืœื™ื ื‘ื’ื™ืœ 10-39 ื”ื•ื 0.2%. ืฉื™ืขื•ืจ ื–ื” ืขื•ืœื” ืขื ื”ื’ื™ืœ ื•ืžื’ื™ืข ืœ-3.6% ื‘ื’ื™ืœ 60-69 ื•ืœ-14.8% ืžืขืœ ื’ื™ืœ 80.
ืœืคื™ ื”ื ื—ื™ื•ืช ืžืฉืจื“ ื”ื‘ืจื™ืื•ืช, ื—ืฉื“ ืœื–ื™ื”ื•ื ื‘ื ื’ื™ืฃ ืงื™ื™ื ื›ืืฉืจ ืงื™ื™ื ืื—ื“ ืžื”ื‘ืื™ื: ื—ื•ื ืžืขืœ 38 ืžืขืœื•ืช ืื• ืฉื™ืขื•ืœ ืื• ืงื•ืฉื™ ื‘ื ืฉื™ืžื” ืื• ืชืกืžื™ืŸ ื ืฉื™ืžืชื™ ืื—ืจ, ื•ื‘ื ื•ืกืฃ ื”ื™ื” ืžื’ืข ื”ื“ื•ืง ืขื ื—ื•ืœื” 19 COVID-ืžื•ื›ื—. "ืžื’ืข ื”ื“ื•ืง" ืžื•ื’ื“ืจ ื›:

1. ืฉื”ื™ื™ื” ื‘ืžืจื—ืง ืฉืœ ืขื“ 2 ืžื˜ืจ, ื‘ืžืฉืš 15 ื“ืงื•ืช ืœืคื—ื•ืช ืขื ื—ื•ืœื” 19 COVID-ืžื•ื›ื—.
2. ืขื‘ื•ื“ื” ืฆืžื•ื“ื” ืื• ืฉื”ื™ื™ื” ื‘ืื•ืชื• ืžืชื—ื ืฉืœ ื—ื•ืœื” COVID-19.
3. ื ืกื™ืขื” ื™ื—ื“ ืขื ื—ื•ืœื” 19-COVID ื‘ื›ืœ ืืžืฆืขื™ ืชื—ื‘ื•ืจื” (ื‘ืงืจื‘ื” ืฉืœ ืขื“ ืฉื ื™ ืžื•ืฉื‘ื™ื).
4. ื‘ื ื™ ื‘ื™ืช ืฉืœ ื—ื•ืœื” 19COVID-.
ืžื›ื™ื•ื•ืŸ ืฉืื™ืŸ ืขื“ื™ื™ืŸ ื˜ื™ืคื•ืœ ืžื•ื›ื— ืื• ื—ื™ืกื•ืŸ ืœื•ื™ืจื•ืก, ืืžืฆืขื™ ื”ื”ื’ื ื” ื”ื—ืฉื•ื‘ื™ื ืžืคื ื™ ื”ื“ื‘ืงื” ื‘ื ื’ื™ืฃ ื”ื ืžื ื™ืขืช ืžื’ืข ื•ื”ืขื‘ืจื” ื˜ื™ืคืชื™ืช. ื”ืžืœืฆื•ืช ื”ื—ื‘ืจื” ื”ื™ืฉืจืืœื™ืช ืœื ื•ื™ืจื•ืื™ืžื•ื ื•ืœื•ื’ื™ื” ื•ื”ืื’ื•ื“ื” ื”ื™ืฉืจืืœื™ืช ืœื˜ืจืฉืช ื ืคื•ืฆื” ืœื—ื•ืœื™ ื˜ืจืฉืช ื ืคื•ืฆื” ื”ืŸ:
ื”ืžืœืฆื•ืช ื›ืœืœื™ื•ืช
1. ืœื”ืžื ืข ืžืฉื”ื™ื” ื‘ืžืจื—ื‘ ืฆื™ื‘ื•ืจื™, ื‘ืคืจื˜ ื‘ืื–ื•ืจื™ื ืœื ืžืื•ื•ืจืจื™ื, ื•ืžื ืกื™ืขื•ืช ื‘ืชื—ื‘ื•ืจื” ืฆื™ื‘ื•ืจื™ืช
2. ืœืฉืžื•ืจ ืžืจื—ืง ืฉืœ ื™ื•ืชืจ ืžืฉื ื™ ืžื˜ืจ ืžืื ืฉื™ื ืื—ืจื™ื, ื‘ืคืจื˜ ืื ื”ื ื—ื•ืœื™ื, ืžืฉืชืขืœื™ื ืื• ืžืชืขื˜ืฉื™ื
3. ื‘ื–ืžืŸ ืขื™ื˜ื•ืฉ ืื• ืฉื™ืขื•ืœ, ื™ืฉ ืœื›ืกื•ืช ืืช ื”ืคื” ื•ื”ืืฃ ื‘ื—ืœืง ื”ืคื ื™ืžื™ ืฉืœ ื”ืžืจืคืง
4. ืœื”ืงืคื™ื“ ืขืœ ืฉื˜ื™ืคืช ื™ื“ื™ื™ื ืœืขื™ืชื™ื ืชื›ื•ืคื•ืช ื‘ืžื™ื ื•ืกื‘ื•ืŸ ื‘ืžืฉืš ืœืคื—ื•ืช 20 ืฉื ื™ื•ืช ื•ืขืœ ืฉื™ืžื•ืฉ ื‘ืžื’ื‘ื•ื ื™ื ืื• ื’'ืœ ืขืœ ื‘ืกื™ืก ืืœื›ื•ื”ื•ืœ (ืœืคื—ื•ืช 60%) ื‘ื”ื™ืขื“ืจ ืžื™ื ื•ืกื‘ื•ืŸ
5. ืœื”ืžื ืข ืžืžื’ืข ื”ื™ื“ื™ื™ื ื‘ืคื ื™ื, ืคื”, ืืฃ, ืขื™ื ื™ื™ื
6. ืœื”ืžื ืข ื›ื›ืœ ื”ืืคืฉืจ ืžืžื’ืข ื‘ื™ื“ ื—ืฉื•ืคื” ืขื ื—ืคืฆื™ื ื”ื—ืฉื•ืคื™ื ืœืžื’ืขื™ื ืจื‘ื™ื ื‘ืžืงื•ืžื•ืช ืฆื™ื‘ื•ืจื™ื™ื (ืžื–ื•ื–ื•ืช, ืœื—ืฆื ื™ ืžืขืœื™ื•ืช, ื™ื“ื™ื•ืช ืฉืœ ื“ืœืชื•ืช ื•ื›ื•')
7. ืœื ืงื•ืช ื•ืœื—ื˜ื ืืช ื”ื‘ื™ืช ืžืžื—ื•ืœืœื™ ืžื—ืœื•ืช, ื‘ืคืจื˜ ืฉื•ืœื—ื ื•ืช, ื™ื“ื™ื•ืช, ืžืชื’ื™ ื—ืฉืžืœ, ื›ื™ื•ืจื™ื ื•ืืกืœื•ืช
8. ื”ื™ื›ืŸ ืฉืžืชืืคืฉืจ, ื™ืฉ ืœื”ืขื“ื™ืฃ ื‘ืชืงื•ืคื” ื–ื• ื‘ื™ืงื•ืจืช ืจืคื•ืื™ืช ื•ื•ื™ืจื˜ื•ืืœื™ืช (ื‘ื˜ืœืคื•ืŸ, ืกืงื™ื™ืค ื•ื›ื•') ืขืœ ืคื ื™ ื‘ื™ืงื•ืจื™ ืคื ื™ื ืืœ ืคื ื™ื ื‘ืžืจืคืื”. ื‘ืžืงืจื” ืฉืœ ื‘ื™ืงื•ืจ ื‘ืžืจืคืื” ืื• ื‘ื‘ื™ืช ื”ื—ื•ืœื™ื, ืžื•ืžืœืฅ ืœื”ืฉืชืžืฉ ื‘ืžืกื›ืช ืืฃ-ืคื”.
9. ื™ืฉ ืœื”ื“ื’ื™ืฉ ืฉืœืื ืฉื™ื ืขื ื˜ืจืฉืช ื ืคื•ืฆื” ืฉืœื ืžืงื‘ืœื™ื ื˜ื™ืคื•ืœื™ื
ื”ืžื“ื›ืื™ื ืืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ, ืื™ืŸ ืกื™ื›ื•ืŸ ืžื•ื’ื‘ืจ ืœื—ืœื•ืช ื‘ื ื’ื™ืฃ ื”ืงื•ืจื•ื ื”. ืขื ื–ืืช, ื—ื•ืœื™ื ืžื‘ื•ื’ืจื™ื ืื• ื‘ืžืฆื‘ ืงืฉื” ื•ืขื ืžื—ืœื•ืช ื›ืจื•ื ื™ื•ืช ื ื•ืกืคื•ืช ืฆืจื™ื›ื™ื ืœื ืงื•ื˜ ื‘ืืžืฆืขื™ ื–ื”ื™ืจื•ืช ืžื•ื’ื‘ืจื™ื.

ื”ืžืœืฆื•ืช ื”ื ื•ื’ืขื•ืช ื‘ื˜ื™ืคื•ืœื™ื ืชืจื•ืคืชื™ื™ื ื‘ื˜ืจืฉืช ื ืคื•ืฆื”

1. ื™ืฉ ื—ืฉื™ื‘ื•ืช ืจื‘ื” ื‘ืงื‘ืœื” ืจืฆื•ืคื” ืฉืœ ื˜ื™ืคื•ืœ ืžื•ื ืข ื›ืคื™ ืฉื”ื•ืžืœืฅ ืœื›ืœ ืžื˜ื•ืคืœ ื‘ืžืจืคืืชื•. ื”ืชืจื•ืคื•ืช ืœื˜ืจืฉืช ื ืคื•ืฆื” ืžื•ื•ืกืชื•ืช ืื• ืžื“ื›ืื•ืช ืืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ ื•ื—ืœืงืŸ ืขืœื•ืœื•ืช ืœื”ื’ื‘ื™ืจ ืืช ื”ืกื™ื›ื•ืŸ ืœืกื™ื‘ื•ื›ื™ื ืžื–ื™ื”ื•ื ื‘- COVID-19. ื™ืฉ ืœืฉืงื•ืœ ืกื™ื›ื•ืŸ ื–ื” ื‘ืื•ืคืŸ ืื™ืฉื™ ืืœ ืžื•ืœ ื”ืกื™ื›ื•ืŸ ื‘ื”ืคืกืงืช ื”ื˜ื™ืคื•ืœ.
2. ื‘ืžื™ื“ื” ื•ืื™ืŸ ืชืกืžื™ื ื™ ืžื—ืœื”, ื’ื ืื ืฉื•ื”ื™ื ื‘ื‘ื™ื“ื•ื“, ื ื™ืชืŸ ืœื”ืžืฉื™ืš ื‘ื˜ื™ืคื•ืœ ื›ืจื’ื™ืœ
3. ื‘ืžื™ื“ื” ื•ื”ื•ืคื™ืขื• ืกื™ืžื ื™ ืžื—ืœื” (ื‘ืคืจื˜ ื—ื•ื, ืฉื™ืขื•ืœ ืื• ืงื•ืฆืจ ื ืฉื™ืžื”) ืื• ืฉืงื™ื™ืžืช ื‘ื“ื™ืงื” ื—ื™ื•ื‘ื™ืช ืœื ื’ื™ืฃ, ื™ืฉ ืœื”ืฉืืจ ื‘ื‘ื™ืช, ืœื”ื•ื“ื™ืข ืœืจื•ืคื ื”ืžืฉืคื—ื” ื•ืœืจื•ืคื ื”ืžื˜ืคืœ ื‘ืžืจืคืืช ื˜ืจืฉืช ื ืคื•ืฆื” ื•ืœืฉืชืฃ ืื•ืชื ื‘ืชื•ืคืขื•ืช ื•ื‘ื—ืฉื“ ืœ-COVID-19 ืœืฆื•ืจืš ื”ื—ืœื˜ื” ืขืœ ื‘ื“ื™ืงืช ื”ื ื’ื™ืฃ, ื˜ื™ืคื•ืœ ื‘ื‘ื™ืช ืื• ื‘ื‘ื™ื”"ื— ื•ื”ืžืฉืš ื”ื˜ื™ืคื•ืœ.
4. ื‘ืžืงืจื” ืฉืœ ื—ื•ื ื’ื‘ื•ื” ื•ื—ืฉื“ ืœืžื—ืœื” ื–ื™ื”ื•ืžื™ืช, ื™ืฉ ืœื“ื•ืŸ ืขื ื”ืจื•ืคื ื”ืžื˜ืคืœ ืขืœ ื”ืฆื•ืจืš ืœื”ืคืกื™ืง ื˜ื™ืคื•ืœื™ื ื‘ื™ื•ืœื•ื’ื™ื™ื ืื• ื˜ื™ืคื•ืœื™ื ื”ืžื“ื›ืื™ื ืืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ ืขื“ ื”ื‘ืจืื” ืžื”ืžื—ืœื” ื”ื–ื™ื”ื•ืžื™ืช.
5. ืœืคื ื™ ื”ืชื—ืœืช ื˜ื™ืคื•ืœ ื—ื“ืฉ ื™ืฉ ืœื“ื•ืŸ ืขื ื”ืจื•ืคื ื”ืžื˜ืคืœ ืขืœ ื”ื˜ื™ืคื•ืœ ื”ืžืชืื™ื ื‘ื™ื•ืชืจ ื‘ื”ืชืื ืœืคืขื™ืœื•ืช ื•ืœืžื”ืœืš ื”ืžื—ืœื” ื”ืื™ื ื“ื™ื‘ื™ื“ื•ืืœื™ืช ื•ืœืื•ืจ ื”ืกื™ื›ื•ืŸ ืœ-COVID-19 ื‘ืื–ื•ืจ. ื‘ื ืกื™ื‘ื•ืช ืžืกื•ื™ื™ืžื•ืช ื›ืžื• ื›ืืฉืจ ืงื™ื™ื ืกื™ื›ื•ืŸ ื’ื‘ื•ื” ืœืœืงื•ืช ื‘ื–ื™ื”ื•ื ื‘ื ื’ื™ืฃ ื™ืฉ ืœืฉืงื•ืœ ืชืจื•ืคื•ืช ืฉืื™ื ืŸ ืžื•ืจื™ื“ื•ืช ืืช ืžืกืคืจ ื”ืœื™ืžืคื•ืฆื™ื˜ื™ื.
6. ื™ืฉ ืœืฉืงื•ืœ ื“ื—ื™ื™ืช ื˜ื™ืคื•ืœ ื‘ืชื›ืฉื™ืจื™ื ืžื“ื›ืื™ ื—ื™ืกื•ืŸ ืœื˜ื•ื•ื— ืืจื•ืš ื›ืœืžื˜ืจื“ื”, ืื•ืงืจื‘ื•ืก ื•ืžื‘ื ืงืœืื“.
7. ื ื™ืชืŸ ืœื”ืžืฉื™ืš ื˜ื™ืคื•ืœ ื‘ืชื›ืฉื™ืจื™ื™ื ืงื•ืคืงืกื•ืŸ , ืื™ื ื˜ืจืคืจื•ื ื™ื, ื˜ืงืคื™ื“ืจื”, ืคื™ื ื’ื•ืœื™ืžื•ื“/ ื’ื™ืœื ื™ื” , ื˜ืจื™ืคืœื•ื ื•ืžื™ื“/ ืื•ื‘ื’'ื™ื•, ื˜ื™ืกื‘ืจื™. ื™ืฉ ืœื”ืคืขื™ืœ ืฉื™ืงื•ืœ ื“ืขืช ืœื’ื‘ื™ ื”ืžืฉืš ื”ื˜ื™ืคื•ืœ ืฉื™ื›ืœื•ืœ ื‘ื“ื™ืงืช ืกืคื™ืจืช ื“ื (ืœื™ืžืคื•ืฆื™ื˜ื™ื) ืœื’ื‘ื™ ื”ืชื›ืฉื™ืจื™ื ืฉืžื‘ื•ืฆืขืช ืœื’ื‘ื™ื”ื ื‘ื™ืงื•ืจืช ืกืคื™ืจืช ื“ื ืชืงื•ืคืชื™ืช
8. ื‘ื–ืžืŸ ื–ื™ื”ื•ื ืคืขื™ืœ ื™ืฉ ืœื”ื•ื•ืขืฅ ืขื ื”ื ื•ื™ืจื•ืœื•ื’ ื”ืžื˜ืคืœ ื‘ื™ื—ืก ืœื”ืžืฉืš ื”ื˜ื™ืคื•ืœ ืฉื ืœืงื—.
9. ื™ื™ืชื›ืŸ ืฉื”ืจื•ืคื ืฉืœืš ื™ืžืœื™ืฅ ืขืœ ื‘ื™ืฆื•ืข ืชื›ื•ืฃ ื™ื•ืชืจ ืฉืœ ืกืคื™ืจื•ืช ื“ื ืฉื™ืขื–ืจื• ืœืขืงื•ื‘ ืžืงืจื•ื‘ ืื—ืจื™ ืกืคื™ืจืช ื”ืœื™ืžืคื•ืฆื™ื˜ื™ื, ื”ืกื™ื›ื•ืŸ ื”ืงืฉื•ืจ ื‘ื˜ื™ืคื•ืœ ื•ื”ืฆื•ืจืš ื‘ืžืชืŸ ืื• ื“ื—ื™ื™ืช ืงื•ืจืก ื˜ื™ืคื•ืœื™.

Karussis interview in Jerusalem report magazine about the stem cell trials at Hadassah
29/07/2016

Karussis interview in Jerusalem report magazine about the stem cell trials at Hadassah

21/03/2016

Prof Karussis in "Haim Bari" (Prof Karasso, art 10) for ALS trial and stem cells 2-2016

21/03/2016

Interview with Prof Karussis in emed about ALS stem cell trial 3-2016

http://lifestyle.nana10.co.il/Article/?ArticleID=1176987
25/02/2016

http://lifestyle.nana10.co.il/Article/?ArticleID=1176987

ื”ื™ืœื“ ื—ื•ื–ืจ ืžื”ื’ืŸ ืขื ื“ื™ืžื•ืžื™ื ืชืช ืขื•ืจื™ื™ื ืžื‘ืœื™ ืฉืงื™ื‘ืœ ืžื›ื”? ื™ื™ืชื›ืŸ ืฉืžื“ื•ื‘ืจ ื‘ื˜ืจื•ืžื‘ื•ืฆื™ืคื•ื ื™ื” ืื™ืžื•ื ื™ืช, ืžื—ืงืจ ื—ื“ืฉ ืžื’ืœื” ืฉื˜ื™ืคื•ืœ ื‘ืชืื™ ื’ื–ืข ื™ื›ื•ืœ ืœื™ื™ืฆื‘ ืืช ืžืฆื‘ื ืฉืœ ื—ื•ืœื™ ALS

19/09/2015

Prof. Karussis in "Haim Bari" with Prof. Karasso about the new trial in MS with stem cells at Hadassah

02/08/2015
28/07/2015

The Hadassah Centre for MS and Neuroimmunology provides a multi-disciplinary approach to the problems related to MS and other neuroinflammatory diseases

Address

Ein Kerem
Jerusalem
91120

Website

Alerts

Be the first to know and let us send you an email when The Center for Multiple Sclerosis and Neuroimmunology at Hadassah posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share